The burden of rare cancers in the United States-Reference-Cited by-同舟云学术

The burden of rare cancers in the United States

Published:2017-05-19 Issue:4 Volume:67 Page:261-272
ISSN:0007-9235
Container-title:CA: A Cancer Journal for Clinicians
language:en
Short-container-title:CA: A Cancer Journal for Clinicians

Author:

DeSantis Carol E.¹^ORCID,Kramer Joan L.²,Jemal Ahmedin³

Affiliation:

1. Director, Breast and Gynecological Cancer Surveillance, Surveillance and Health Services Research; American Cancer Society; Atlanta GA

2. Assistant Professor of Hematology and Medical Oncology, Emory University School of Medicine; Atlanta GA

3. Vice President, Surveillance and Health Services Research; American Cancer Society; Atlanta GA.

Publisher

Wiley

Subject

Oncology,Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.3322/caac.21400/fullpdf

Reference32 articles.

1. The value of research collaborations and consortia in rare cancers;Blay;Lancet Oncol.,2016

2. The promise and challenges of rare cancer research;Komatsubara;Lancet Oncol.,2016

3. US Food and Drug Administration Orphan Drug Act-Relevant Excerpts fda.gov/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/ucm364750.htm 2017

4. The occurrence of rare cancers in US adults, 1995-2004;Greenlee;Public Health Rep.,2010

5. Rare cancers are not so rare: the rare cancer burden in Europe;Gatta;Eur J Cancer.,2011

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14;Gynecologic Oncology;2024-11

2. Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers;Clinical Pharmacology & Therapeutics;2024-08-16

3. Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy;iScience;2024-08

4. Challenges of diagnosing rare cancers in primary care;British Journal of General Practice;2024-07-25

5. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort;Journal for ImmunoTherapy of Cancer;2024-07